MRK Near $131: A Tokenized Wrapper Keeps the Price and Drops the Dividend

TL;DR

I went looking for a clean way to hold Merck through a token, and what I found is a wrapper that hugs the stock price almost perfectly while sitting on a float so thin it changes how you should trade it. Merck is a dividend-and-Keytruda story, and the tokenized version keeps the price and drops the two things that actually make MRK worth holding: the cash yield and the ability to size a position around the 2028 patent binary. Here is the trade in four lines.

• The Tape: MRK reference price sits near $131.25, and the tokenized average is $131.37 — a spread of +$0.12 (+0.09%) [As of July 27, 2026 (UTC), CoinMarketCap RWA]. The token tracks; that part works.
• The Mint: Ondo Assets is the issuer, live on Ethereum and Solana, with a tokenized market cap CMC pins at $42.78M in aggregate — but the single Ethereum MRKon wrapper shows just $16.93K across 129 tokens and 63 holders [CoinMarketCap MRKon].
• The Risk: Keytruda did $31.7B in 2025 (~55% of pharma revenue) and its US composition patent expires in 2028 [Stocktwits/analysts]. A thin book amplifies every headline gap on that one drug.
• The Hedge: If you want a position you can actually enter and exit at scale, deep 24/7 books like BTC-USDT futures on OneBullex clear size that a 129-token pharma wrapper cannot.

The tape says the token tracks; the float says do not size into it

Start with the good news, because there is some. The tokenized MRK price is genuinely close to the stock. CoinMarketCap's RWA page shows a reference equity price of $131.25 and a tokenized average of $131.37, a premium of +$0.12, or +0.09% [As of July 27, 2026 (UTC), CoinMarketCap RWA]. For a synthetic that lives on-chain while the NYSE tape it mirrors closed at $131.07 on July 24 [stockanalysis.com], that is tight tracking. So-what: peg quality is not the problem here.

The float is. That same RWA page reports a tokenized market cap of $42.78M in aggregate, but click into the actual Ethereum wrapper — Merck Tokenized Stock (Ondo), ticker MRKon — and you see a market cap of $16.93K, a circulating supply of 129.03 tokens, and 63 holders [As of July 27, 2026 (UTC), CoinMarketCap MRKon]. Either number you trust, the conclusion is the same: this is a rounding error against Merck's ~$323.7B equity market cap.

The tight premium is not a promise of tight execution. It is a snapshot of a book so small that a single motivated buyer can set the print. That is the first thing that separates this token from an NYSE share.

Merck is a dividend stock, and the wrapper does not pay the dividend

Here is the part that quietly breaks the thesis for most people who hold MRK. Merck pays $3.40 per share annually, a 2.59% yield, at a $0.85 quarterly rate it just raised, extending a streak of 15 consecutive years of increases [As of July 27, 2026 (UTC), stockanalysis.com dividend]. A large share of the retail case for owning Merck is exactly that: a defensive, low-beta (0.20) pharma name that pays you to wait.

A tokenized price-tracking wrapper does not credit you that dividend. So-what: you keep the volatility and the patent risk and you give up the one component that compensates you for holding a slow compounder. On a growth name where the yield is a footnote, skipping the dividend barely matters. On Merck, the dividend is the reason a lot of the float exists.

One caveat on the scary-looking 93.96% payout ratio: that is GAAP, distorted by one-time deal charges (Cidara ~$9B, proposed Terns ~$5.8B). On the non-GAAP EPS guide of $5.04–$5.16 for 2026 [Hudson Labs], the dividend is comfortably covered. The point stands: it is a real, covered dividend, and the wrapper does not hand it to you.

Keytruda's 2028 cliff is the only number that matters, and a thin book amplifies it

Everything about Merck routes back to one drug. Keytruda generated $31.7 billion in 2025, roughly 55% of pharma revenue, and its core US composition-of-matter patent expires in 2028 [As of July 27, 2026 (UTC), Stocktwits]. There is no comparable single-drug revenue exposure in oncology history.

Merck's defense is real but layered: the subcutaneous QLEX formulation carries independent patents to roughly 2033, method-of-use claims extend to ~2031, and fixed-dose combinations could push some exclusivity out much further [patsnap]. So-what: the cliff is a slope, not a wall, and QLEX uptake (management targets 30–40% by end-2027) is the number to watch on every earnings call, starting with Aug 4, 2026 [stockanalysis.com].

Now connect that to the token. Binary patent and pipeline headlines break on their own schedule — often when the NYSE is shut. A tokenized wrapper trades 24/7, which sounds like a feature until you remember the book is 129 tokens and 63 holders. On a real Keytruda scare, that thin float gaps far harder than the underlying will when the exchange reopens. You are not hedging the binary with the token; you are amplifying it.

The pipeline-and-M&A bet is real, but you cannot trade the catalyst on a 129-token wrapper

Merck is not standing still. New launches — WINREVAIR, the newly FDA-approved oral PCSK9 inhibitor Lipfendra (enlicitide), CAPVAXIVE, and QLEX — are the post-Keytruda engine, and management raised FY2026 sales guidance to $65.8B–$67.0B [Hudson Labs]. On top of that, CEO Robert Davis has signaled Merck is "not done" on deals, and retail sentiment on Stocktwits is actively betting on the next biotech buyout to shore up the pipeline [Stocktwits]. Treat that chatter as community second-hand signal, not confirmed news.

So-what: this is a catalyst-driven name for the next 24 months. Trading catalysts means you need to enter before the print and exit into liquidity after it. A wrapper with ~$680K in daily volume cannot absorb a real reaction without punishing slippage. The bet may be right; the venue is wrong.

A +0.09% premium is not the risk; the ATH-to-ATL swing on the wrapper is

It is tempting to look at the +0.09% premium and conclude the token is harmless. Look at its own history instead. MRKon printed an all-time high of $143.91 on June 14, 2026 and an all-time low of $106.20 on January 29, 2026 [As of July 27, 2026 (UTC), CoinMarketCap MRKon] — a roughly 26% peak-to-trough range in about five months, while the underlying stock stayed pinned near its 52-week high of $131.74 in a $76.66–$131.74 band [stockanalysis.com].

So-what: the equity did not move like that. The wrapper did, because thin books wander from fair value between the rare moments a large trade forces them back. Your risk on this token is not the headline premium; it is the gap you eat when you need to trade and nobody is on the other side at fair value.

What I would actually do with pharma exposure right now

If I want Merck for what Merck is — a defensive, dividend-paying pharma anchor with a 15-year raise streak and a covered payout — I hold the real share, collect the 2.59% yield, and watch QLEX uptake and the 2028 cliff on each earnings call. The tokenized wrapper gives me the price and takes the dividend, so it fails the exact reason I would own this name.

If what I actually want is something to trade — 24/7 exposure, real depth, the ability to size in and out around catalysts — then a 129-token pharma wrapper is the wrong tool. I would rather put that risk into a market built for it. On OneBullex, the 300 SPARTANS glass-box bots let me automate an entry-and-exit strategy with full visibility into the logic, and deep books like BTC-USDT futures on OneBullex clear size the pharma float simply cannot. MRK is a hold-the-share story; it is not a tokenized-trading story.

FAQ

Is tokenized MRK the same as owning Merck stock?
No. It tracks the price closely (+0.09% premium as of July 27, 2026 (UTC), per CoinMarketCap), but it does not give you the NYSE share, and critically it does not pass through Merck's $3.40 annual dividend. You get price exposure without the yield or the shareholder rights.

Why is the tokenized market cap so small?
CoinMarketCap's RWA page shows a $42.78M aggregate, but the single Ethereum MRKon wrapper is just $16.93K across 129 tokens and 63 holders. Against Merck's ~$323.7B equity market cap, the tokenized float is a rounding error, and thin floats mean poor execution.

What is the biggest risk to Merck itself?
Keytruda. It was ~55% of pharma revenue ($31.7B in 2025), and its US composition patent expires in 2028. Merck is defending with the QLEX subcutaneous formulation (patents to ~2033), new launches, and M&A, but this single-drug concentration is the whole risk story.

Does the +0.09% premium mean the token is safe?
No. The premium is small right now, but the MRKon wrapper swung from $106.20 to $143.91 in about five months while the stock stayed range-bound. The real risk is slippage on a thin book, not the headline premium.

If I just want something liquid to trade, what is the alternative?
For a position you can actually enter and exit at scale, deep 24/7 crypto markets are built for it. ETH-USDT on OneBullex offers depth a 129-token pharma wrapper cannot match. Create a free OneBullex account to see the order books before you commit capital.

Related reading

Tokenized JNJ: a 43.5M float but 99% is not a tradable book

ABBV Near $259: A $57M Tokenized Float With $56K Volume Is Fiction

LLY Near $1,196: A Tokenized Premium With Depth Only on Ondo Is Not 24/7 Lilly

JPM Near $353: A $39M Dead Float and an Ondo Premium Is Not 24/7 Bank Exposure

UNH Near $421: A Gated $52M Token Cannot Price the DOJ Probe

PG Near $147: A 2.45% Token Premium Eats a Full Year of Dividend

CSCO Near $114: A 3M-Dollar Token Book Is Not the AI Re-Rate

KO Near $82 Before Q2: A Dividend-Less Token Is Not the Staple

COST Near $935 at 50x: A 1,259-Token Float Is Not the Warehouse

bac tokenized rwa price liquidity

Risk disclosure

This content is for educational and informational purposes only and does not constitute financial, investment, legal, or tax advice. Crypto assets are highly volatile and may lose value. Always do your own research and consider your financial situation and risk tolerance before making any decision.

Figures reflect CoinMarketCap MRK RWA and token pages, stockanalysis.com MRK, and CoinGecko Merck tokenized totals as of July 27, 2026 (UTC). Re-verify before acting.